Virus injection takes on deadly brain tumor in new trial
NCT ID NCT07145047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether injecting an oncolytic virus directly into brain tumors can treat recurrent glioblastoma, a fast-growing cancer. Twenty participants will receive up to six injections over several weeks, with regular checkups to monitor safety and tumor response. The goal is to find a tolerable dose and see if the virus can slow or shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic virus
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is an early phase 1/2 trial with only 20 participants, so results may not apply broadly. The virus may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mianyang Central Hospital
RECRUITINGMianyang, Sichuan, 621000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••